Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

Merck & Co. stands out among dividend stocks, offering a solid 3.50% yield and 14 consecutive years of dividend growth.

Merck has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its cancer ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Maple Open House Weekend in Vermont is more than a calendar event — it's a community celebration of nature’s rhythms. On ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...